Biotech Values

[mcbio]

Everyone knew the company needed cash, and they got cash at a discount of only 2% to Tuesday’s closing price with no warrants. That’s a positive development for a clinical-stage biotech company.

Thanks DD. Makes sense.

Separately, which side of the fence are you on vis-a-vis ACHN: my optimistic take on ACHN that there will be room for an HCV PI, like 1625 or 2684, in the future of HCV treatment, and in particular enough room to have a meaningful impact on ACHN's current market cap or oc631's bearish take on ACHN in that the VRUS nukes will solely dominate the future of HCV treatment, leaving little to no room for any HCV drugs from other classes?